Journal Papers, Abstracts, and Commentaries
| |
Brief Report: The Effect of Antiretroviral Therapy and CD4 Count on Markers
of Infectiousness in HIV-Associated Tuberculosis.
van Halsema CL, Fielding KL, Chihota VN, et al
J Acquir Immune Defic Syndr.
2015 Sep 1;70(1):104-108.
Abstract
Impact of three empirical anti-tuberculosis treatment
strategies for people initiating antiretroviral therapy.
Van Rie A, Westreich D, Sanne I.
Int J Tuberc Lung Dis.
2014 Nov;18(11):1340-6.
Abstract
FULL-TEXT PDF ARTICLE
The
impact of HAART initiation timing on HIV-TB co-infected patients, a
retrospective cohort study.
Yang CH, Chen KJ, Tsai JJ, et al
BMC Infect Dis. 2014
Jun 4;14(1):304
Paper
When to start antiretroviral therapy during tuberculosis
treatment?
Naidoo K, Baxter C, Abdool Karim SS
Curr Opin Infect Dis.
2012 Nov 22.
Abstract
Timing of Initiation of Antiretroviral Therapy in Human
Immunodeficiency Virus (HIV)-Associated
Tuberculous Meningitis.
Török ME, Yen NT, Chau TT, et al
Clin Infect Dis. 2011
Jun;52(11):1374-83.
Abstract
Effects of Antiretroviral Therapy on Immune Function of
HIV-infected Adults with Pulmonary
Tuberculosis and CD4+ >350 Cells/mm3.
Lancioni CL, Mahan CS, Johnson DF, et al
J Infect Dis. 2011 Apr;203(7):992-1001.
Abstract
Timing of Antiretroviral Therapy for HIV in the Setting of TB
Treatment.
Piggott DA, Karakousis PC
Clin Dev Immunol.
2011;2011:103917
Abstract |
Initiating antiretrovirals during tuberculosis
treatment: a drug safety review.
Gengiah TN, Gray AL, Naidoo K, Karim QA.
Expert Opin Drug Saf.
2011 Jan 5
Abstract |
Antiretrovirals and isoniazid preventive therapy in the prevention of
HIV-associated tuberculosis in
settings with limited health-care resources.
Lawn SD, Wood R, De Cock KM, et al
Lancet
Infect Dis. 2010 Jul;10(7):489-49
Abstract |
Timing of initiation of antiretroviral drugs during tuberculosis
therapy.
Abdool Karim SS, Naidoo K, et al
N Engl J Med. 2010
Feb 25;362(8):697-706.
Abstract |
Impact of HAART therapy on co-infection of tuberculosis and HIV cases for 9
years in Taiwan.
Tseng SH, Jiang DD, Hoi HS, et al
Am J Trop Med Hyg. 2009
Apr;80(4):675-7
Abstract |
The utility of nucleos(t)ide-only regimens in the treatment of
Mycobacterium tuberculosis-HIV-1
coinfection.
Armstrong-James D, Menon-Johansson A, Pozniak A.
AIDS. 2009 Mar 19.
Abstract
|
|
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
| |
Is there a need to increase the dose of efavirenz during concomitant
rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB
pharmagene study.
Habtewold A, Makonnen E, Amogne W,
et al
Pharmacogenomics.
2015 Apr 1:1-17.
Abstract
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains
variability in long-term efavirenz plasma exposure.
Mukonzo JK, Nanzigu S, Waako P, et al
Pharmacogenomics.
2014 Aug;15(11):1423-1435.
Abstract
FULL-TEXT ARTICLE
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure
and virological failure relationship.
Bhatt NB, Baudin E, Meggi B, da Silva C,
et al
J Antimicrob Chemother.
2014 Sep 18.
Paper
Effects of rifampin-based antituberculosis therapy on plasma
efavirenz concentrations in children vary by CYP2B6 genotype.
McIlleron HM, Schomaker M, Ren Y, et al
AIDS. 2013 Jul
31;27(12):1933-40.
Abstract
FULL-TEXT ARTICLE
T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive
Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
da Silva TP, Giacoia-Gripp CB, et al
PLoS One.
2013 Jun 19;8(6):e66095.
Paper
Impact of Pharmacogenetic Markers of CYP2B6, Clinical
Factors, and Drug-Drug Interaction on Efavirenz Concentrations in
HIV/Tuberculosis Co-Infected Patients.
Manosuthi W, Sukasem C, Lueangniyomkul A,
et
al
Antimicrob Agents Chemother.
2012 Dec 17
Abstract |
CYP2B6 G516T and ABCB-1 C3435T polymorphisms: implications
for efavirenz-associated liver toxicity in HIV/tuberculosis co-infected
Thai adults.
Uttayamakul S, Manosuthi W, Likanonsakul S, et al
J Int AIDS Soc.
2012 Nov 11;15(6):18409.
Abstract
Impact of pharmacogenetic markers of CYP2B6 and clinical
factors on plasma efavirenz level in HIV/tuberculosis co-infected Thai
patients.
Manosuthi W, Sukasem C, Lueangniyomkul A,
et al
J Int AIDS Soc. 2012 Nov 11;15(6):18410
Abstract
FULL-TEXT ARTICLE
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and
Rifampicin Based Anti-TB Drug Induced
Liver Injury in TB-HIV Infected Patients.
Yimer G, Ueda N, Habtewold A, Amogne W,
et al
PLoS One. 2011;6(12):e27810
Paper |
The influence of tuberculosis treatment on efavirenz clearance in patients
co-infected with HIV and tuberculosis.
Gengiah TN, Holford NH, Botha JH, et al
Eur J Clin Pharmacol.
2011 Nov 23.
Abstract
Efficacy and Safety of Once-Daily Nevirapine- or
Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis:
A
Randomized Clinical Trial.
Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al
Clin Infect Dis. 2011
Oct;53(7):716-24.
Abstract
Efavirenz and rifampicin in the South African context: is there a need to
dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C, Cohen K, Conradie F,
et al
Antivir Ther. 2011;16(4):527-34.
Abstract
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and
nevirapine
levels when co-administered with rifampicin in HIV/TB co-infected Thai
adults.
Uttayamakul S, Likanonsakul S, Manosuthi W, et al
AIDS Res Ther.
2010 Mar 26;7(1):8
Abstract |
Administration of efavirenz (600 mg/day) with rifampicin results
in highly variable levels
but excellent clinical outcomes in patients treated for
tuberculosis and HIV.
Friedland G, Khoo S, Jack C, Lalloo U.
J Antimicrob Chemother. 2006 Oct 10;
Abstract
|
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
| |
Post-Treatment Effect of Isoniazid Preventive Therapy on
Tuberculosis Incidence in HIV Infected Individuals on Antiretroviral
Therapy.
Sumner T, Houben RM, Rangaka MX,
et al
AIDS. 2016 Mar 4.
Abstract
FULL-TEXT ARTICLE
Effect of
isoniazid preventive therapy on tuberculosis or death in persons with
HIV: a retrospective cohort study
Ayele HT, van Mourik MS, Bonten MJ.
BMC Infect Dis.
2015 Aug 13;15:334.
Paper
FULL-TEXT ARTICLE
Factors Associated with Adherence to Treatment with Isoniazid for the Prevention
of Tuberculosis amongst People Living with HIV/AIDS: A Systematic Review of
Qualitative Data.
Makanjuola T, Taddese HB, Booth A.
PLoS One. 2014 Feb 3;9(2):e87166
Paper
Anti-tuberculosis treatment outcomes in HIV-infected adults
exposed to isoniazid preventive therapy in Botswana
Sibanda T, Tedla Z, Nyirenda S, et al
Int J Tuberc Lung Dis.
2013 Feb;17(2):178-85
Abstract |
Isoniazid prophylaxis started at 3-4 months of life does not prevent
tuberculosis disease or infection in both HIV-infected
and uninfected children.
Iro MA, Brown N.
Arch Dis Child Educ Pract Ed.
2012 Nov 17
Abstract
6-month versus 36-month isoniazid preventive treatment for tuberculosis in
adults with HIV infection |
in Botswana: a randomised, double-blind, placebo-controlled trial.
Samandari T, Agizew TB, Nyirenda S, et al
Lancet. 2011 Apr 12.
Abstract |
|
Journal Papers, Abstracts, and Commentaries
|
| |
Impact of lopinavir/ritonavir or nevirapine on bedaquiline
exposures: potential implications for patients with TB/HIV co-infection
Svensson EM, Dooley KE, Karlsson MO.
Antimicrob Agents Chemother.
2014 Aug 11
Abstract
Double-dose lopinavir-ritonavir in combination with
rifampicin-based anti-tuberculosis treatment in South Africa.
Sunpath H, Winternheimer P, Cohen S,
et
al
Int J Tuberc Lung Dis.
2014 Jun;18(6):689-93.
Abstract
FULL-YEXT ARTICLE
Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis
Co-Infected Adults in South Africa.
Murphy RA, Marconi VC, Gandhi RT
PLoS One. 2012;7(9):e44793
Paper
Population pharmacokinetics of lopinavir and ritonavir in combination
with rifampicin-based
antitubercular treatment in HIV-infected children.
Zhang C, McIlleron H, Ren Y,
et al
Antivir Ther. 2012;17(1):25-33.
Abstract |
HIV and TB coinfection: using adjusted doses of
lopinavir/ritonavir with rifampin.
Curran A, Ribera E.
Expert Rev Anti Infect Ther.
2011 Dec;9(12):1115-8.
Abstract
|
|
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
| |
FULL-TEXT ARTICLE
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure
and virological failure relationship.
Bhatt NB, Baudin E, Meggi B, da Silva C,
et al
J Antimicrob Chemother.
2014 Sep 18.
Paper
Impact of lopinavir/ritonavir or nevirapine on bedaquiline
exposures: potential implications for patients with TB/HIV co-infection
Svensson EM, Dooley KE, Karlsson MO.
Antimicrob Agents Chemother.
2014 Aug 11
Abstract
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis:
a systematic review and meta-analysis.
Jiang HY, Zhang MN, Chen HJ, et al
Int J Infect Dis. 2014 Jun 6.
Abstract
The pharmacokinetics of nevirapine when given with isoniazid in
South African HIV-infected individuals
Decloedt EH, Mwansa-Kambafwile J, van der Walt JS, et al
Int J Tuberc Lung Dis.
2013 Mar;17(3):333-5.
Abstract |
FULL-TEXT PDF ARTICLE
The antiretroviral efficacy of highly active antiretroviral therapy
and plasma nevirapine concentrations in
HIV-TB co-infected Indian patients receiving rifampicin based
antituberculosis treatment.
Sinha S, Dhooria S, Kumar S, et al
AIDS Res Ther. 2011
Nov 2;8(1):41
Paper |
Treatment outcomes of patients co-infected with HIV and tuberculosis
who received a
nevirapine-based antiretroviral regimen: a four-year prospective
study.
Manosuthi W, Tantanathip P, Chimsuntorn S,
et al
Int J Infect Dis.
2010 Sep 27.
Abstract |
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and
nevirapine
levels when co-administered with rifampicin in HIV/TB co-infected Thai
adults.
Uttayamakul S, Likanonsakul S, Manosuthi W, et al
AIDS Res Ther.
2010 Mar 26;7(1):8
Abstract |
Outcomes and safety of concomitant nevirapine and rifampicin treatment
under
programme conditions in Malawi.
Moses M, Zachariah R, Tayler-Smith K, Misinde D, et al
Int J Tuberc Lung Dis.
2010 Feb;14(2):197-202.
Abstract |
Reversible reduction of nevirapine plasma concentrations during
rifampicin treatment in patients
coinfected with HIV-1 and tuberculosis.
Matteelli A, Saleri N, Villani P, et al
J Acquir Immune Defic Syndr.
2009 Sep 1;52(1):64-9
Abstract |
Nevirapine levels after discontinuation of rifampicin therapy and 60-week
efficacy of
nevirapine-based
antiretroviral therapy in HIV-infected patients with tuberculosis.
Manosuthi W, Ruxrungtham K, Likanonsakul S, et al
Clin Infect Dis. 2007 Jan 1;44(1):141-4.
Abstract
|
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
| |
Raltegravir for the treatment of patients co-infected
with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre,
phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B, De Castro N, Arnold V, et al.
Lancet
Infect Dis. 2014 Jun;14(6):459-67.
Abstract
Raltegravir for the treatment of patients co-infected
with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre,
phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B, De Castro N, Arnold V, et al
Lancet Infect Dis.
2014 Apr 9.
Abstract
Is chewed raltegravir an option to care HIV-infected
patients with active tuberculosis?
Gervasoni C, Riva A, Impagnatiello C,
e6 al
Clin Infect Dis.
2013 Apr 24.
Abstract |
Journal Papers, Abstracts, and Commentaries
| |
Pharmacokinetics of Rifampicin and Isoniazid in
Tuberculosis-HIV Co-infected Patients Receiving Nevirapine or Efavirenz
Based Antiretroviral Treatment (ANRS 12214 study).
Bhatt NB, Barau C, Amin A, et al
Antimicrob Agents Chemother.
2014 Mar 24
Abstract
Rifampin mono-resistant tuberculosis and HIV co-morbidity
in California, 1993-2008: A Retrospective Cohort Study.
Prach LM, Pascopella L, Barry PM, et al
|
AIDS. 2013 Jul 9.
Abstract
Efavirenz and rifampicin in the South African context: is there a need to
dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C, Cohen K, Conradie F,
et al
Antivir Ther. 2011;16(4):527-34.
Abstract
Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking
Rifampin Add
Twice-Daily Atazanavir and Ritonavir.
Haas DW, Koletar SL, Laughlin L, et al
J Acquir Immune Defic Syndr.
2009 Feb
Abstract
|
|
Journal Papers, Abstracts, and Commentaries
Journal Papers, Abstracts, and Commentaries
|
|
HIV/TB
Treatment
Main
New/Newsworthy
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
HIV/TB
Main Page
